Precision Optics Corp Inc Dossier - Source-backed chat

Precision Optics Corp Inc

POCINASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.56

Intrinsic Value $6.91median of 2 methodsbased on filings through 31 Mar 2026

Market Price $4.27Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 62% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+62%)

Data confidence Sign in to view data confidence

Market Cap $46.9M

Enterprise Value $37.6M

Shares Outstanding 10.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Precision Optics Corporation (POCI) is successfully transitioning from a development-heavy boutique optical shop to a high-volume manufacturing partner for major medical technology and aerospace/defense OEMs. The company's proprietary micro-optics, 3D imaging, and digital imaging technologies are highly sticky once integrated into commercial products. Recent financial results for Q3 FY2026 demonstrate a powerful inflection point, with revenue surging 108% year-over-year to a record $8.7 million, gross margins expanding to 23.6%, and Adjusted EBITDA turning positive. Backed by a strengthened balance sheet following a $10 million public offering in March 2026, POCI is well-positioned to scale its production lines and commercialize its robust pipeline of engineering projects.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$8.00

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0010%

Supply chain disruptions, customer delays in program rollouts, or intense competition in the medical device space slow down the production ramp-up. High operational cash burn resumes, eroding the cash cushion from the recent capital raise and delaying the path to consistent GAAP profitability.

Base CaseCentral scenario

$8.0060%

Matches the consensus mean

POCI delivers on its raised FY2026 revenue guidance of $29 million to $31 million, representing 52% to 62% year-over-year growth. The cystoscopy surgery system and satellite communication programs maintain their strong momentum, while newly introduced platforms like the Unity CMOS Imaging Platform continue to gain traction, steadily improving the company's long-term margin profile.

Bull CaseUpside scenario

$9.0030%

Accelerated commercialization of the pipeline projects (with 5 programs expected to enter production in the next 12 months) drives revenue well above the high end of FY2026 guidance. Gross margins expand rapidly toward the 30% target due to manufacturing efficiencies and favorable product mix, leading to sustained GAAP profitability and positive free cash flow.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line momentum with Q3 FY2026 revenue growing 108% YoY to a record $8.7 million.
Inflection in profitability with Adjusted EBITDA turning positive at $0.3 million in Q3 FY2026.
Robust balance sheet with cash reserves bolstered to over $10.6 million following a $10 million public offering in March 2026.
Highly sticky business model with long-term, multi-year production contracts in high-barrier industries like healthcare and aerospace/defense.

Key Investment Risks

Customer concentration risk, with a significant portion of revenue driven by a few major programs (e.g., cystoscopy surgery system and satellite communication program).
Historically unprofitable on a GAAP basis, with a net loss of $5.78 million in FY2025.
Potential supply chain constraints and regulatory hurdles associated with medical device manufacturing.

Thesis Invalidation Triggers

A material reduction or cancellation of orders from key customers in the ophthalmic or aerospace programs.
Gross margins failing to sustain sequential improvements and falling back below 15%.
Significant delays in transitioning the 5 pipeline programs scheduled for production over the next 12 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.